NCT05779553Not yet recruiting
Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression
Evaluation of Serum Tumor Endothelial Marker 1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression
Source: ClinicalTrials.gov · Last updated 22 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Aim of work 1. measurement level of serumTEM1 in CRC patients by ng/ml using ELISA kits . 2. find relation between serum TEM1 level and staging of CRC patients . 3. measurement of serum CEA , CA19-9 levels by ng/ml so we can can compare their levels with serum TEM1 level in CRC patients .
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 14 Jan 2023
- Start date
- 1 May 2023
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Assiut University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT05779553
What you commit to
- Study type: Observational
- Planned participants: 90
- From 1 May 2023 to the primary completion date, 1 Feb 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- chemotherapy
- radiotherapy
- surgical treatment
Other illness
- heart failure
- angina
- gastric cancer.
Other
- liver cirrhosis
- renal cell carcinoma
Who the study is looking for
- 1-newly diagnosed CRC patients.
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.